Silencing of CHD5 gene by promoter methylation in leukemia

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Zhao, Rui ^a   Meng, Fanyi ^a   Wang, Nisha ^a   Ma, Wenli ^a   Yan, Qitao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACTIVATING PROTEIN 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BINDING SITE; BONE MARROW; CHD5 GENE; CHROMATIN IMMUNOPRECIPITATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKEMIA CELL LINE; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PROMOTER REGION; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING;

BINDING SITES; CELL LINE, TUMOR; CPG ISLANDS; DNA HELICASES; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LEUKEMIA; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANSCRIPTION FACTOR AP-2;

EID: 84897984562     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085172     Document Type: Article

References (50)

1. Brodeur GM, Sekhon G, Goldstein MN (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40: 2256-2263. (Pubitemid 8239715)
2. White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, et al. (1995) A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A 92: 5520-5524.
3. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, et al. (2005) Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24: 2684-2694. (Pubitemid 40593096)
4. Piaskowski S, Rieske P, Szybka M, Wozniak K, Bednarek A, et al. (2005) GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet 162: 63-67. (Pubitemid 41278472)
5. Poetsch M, Dittberner T, Woenckhaus C (2003) Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 13: 29-33. (Pubitemid 36269811)
6. Moley JF, Brother MB, Fong CT, White PS, Baylin SB, et al. (1992) Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 52: 770-774.
7. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, et al. (1995) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64: 207-210.
8. Mori N, Morosetti R, Mizoguchi H, Koeffler HP (2003) Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. Br J Haematol 122: 226-230. (Pubitemid 36859607)
9. Mori N, Morosetti R, Spira S, Lee S, Ben-Yehuda D, et al. (1998) Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 92: 3405-3409. (Pubitemid 28492351)
10. Melendez B, Cuadros M, Robledo M, Rivas C, Fernandez-Piqueras J, et al. (2003) Coincidental LOH regions in mouse and humans: evidence for novel tumor suppressor loci at 9q22-q34 in non-Hodgkin's lymphomas. Leuk Res 27: 627-633. (Pubitemid 36398098)
11. Kleer CG, Bryant BR, Giordano TJ, Sobel M, Merino MJ (2000) Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression. Endocr Pathol 11: 137-143. (Pubitemid 30610123)
12. Praml C, Finke LH, Herfarth C, Schlag P, Schwab M, et al. (1995) Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 11: 1357-1362.
13. Cheung TH, Lo KW, Yim SF, Poon CS, Cheung AY, et al. (2005) Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer. Gynecol Oncol 96: 510-515. (Pubitemid 40127157)
14. Bieche I, Champeme MH, Matifas F, Cropp CS, Callahan R, et al. (1993) Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 53: 1990-1994. (Pubitemid 23145715)
15. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM (2003) CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22: 1002-1011. (Pubitemid 36313144)
16. Marfella CG, Imbalzano AN (2007) The Chd family of chromatin remodelers. Mutat Res 618: 30-40. (Pubitemid 46574742)
17. Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, et al. (2012) Mechanisms of CHD5 Inactivation in neuroblastomas. Clin Cancer Res 18: 1588-1597.
18. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, et al. (2009) Distinct high-profile methylated genes in colorectal cancer. PLoS One 4: e7012.
19. Mulero-Navarro S, Esteller M (2008) Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 3: 210-215.
20. Wang X, Lau KK, So LK, Lam YW (2009) CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci 16: 95.
21. Zhao R, Yan Q, Lv J, Huang H, Zheng W, et al. (2012) CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 76: 324-331.
22. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
23. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, et al. (2011) The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
24. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, et al. (2008) Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10: 1253-1258.
25. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
26. Lang J, Tobias ES, Mackie R (2011) Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br J Dermatol 164: 1010-1016.
27. Li M, Zhao H, Zhang X, Wood LD, Anders RA, et al. (2011) Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 43: 828-829.
28. Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, et al. (2008) Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27: 803-810. (Pubitemid 351186313)
29. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, et al. (2011) Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 21: 47-55.
30. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274. (Pubitemid 44571966)
31. Mallette FA, Richard S (2013) JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Rep 2: 1233-1243.
32. Du X, Wu T, Lu J, Zang L, Song N, et al. (2012) Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma. Clin Transl Oncol 15: 198-204.
33. Garcia I, Mayol G, Rodriguez E, Sunol M, Gershon TR, et al. (2010) Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer 9: 277.
34. Wong RR, Chan LK, Tsang TP, Lee CW, Cheung TH, et al. (2011) CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer. Gynecol Obstet Invest 72: 203-207.
35. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, et al. (2007) CHD5 is a tumor suppressor at human 1p36. Cell 128: 459-475. (Pubitemid 46198889)
36. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, et al. (2008) CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 100: 940-949. (Pubitemid 351957513)
37. Wu X, Zhu Z, Li W, Fu X, Su D, et al. (2012) Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res 14: R73.
38. Paul S, Kuo A, Schalch T, Vogel H, Joshua-Tor L, et al. (2013) Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell Rep 3: 92-102.
39. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, et al. (2007) Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971. (Pubitemid 46975753)
40. Prestridge DS (1995) Predicting Pol II promoter sequences using transcription factor binding sites. J Mol Biol 249: 923-932.
41. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367. (Pubitemid 28295292)
42. Williams T, Tjian R (1991) Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev 5: 670-682. (Pubitemid 21905986)
43. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196. (Pubitemid 27435555)
44. Hermann R, Doerfler W(1991) Interference with protein binding at AP2 sites by sequence-specific methylation in the late E2A promoter of adenovirus type 2 DNA. FEBS Lett 281: 191-195.
45. McPherson LA, Baichwal VR, Weigel RJ (1997) Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci U S A 94: 4342-4347. (Pubitemid 27194243)
46. McPherson LA, Weigel RJ (1999) AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. Nucleic Acids Res 27: 4040-4049. (Pubitemid 29479031)
47. Bagchi A, Mills AA (2008) The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551-2556. (Pubitemid 351556249)
48. Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, et al. (1995) Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 83: 160-164.
49. Law ME, Templeton KL, Kitange G, Smith J, Misra A, et al. (2005) Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 160: 1-14. (Pubitemid 40798130)
50. Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, et al. (2012) MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One 7: e29750.